Island Pharmaceuticals: Developing a new drug for a disease that 400m people are diagnosed with a year – now that’s scalable!
Island Pharmaceuticals Managing Director David Foster on 3AW & 2GB Bulls N' Bears Report
Listen to ASX-listed Island Pharmaceuticals Managing Director Dr David Foster talk to Matt Birney on the Bulls N’ Bears Report about Island Pharmaceuticals’ remarkable redevelopment of a drug that was once created to tackle an entirely different disease.
TO LISTEN TO THE ISLAND PHARMACEUTICALS AUDIO INTERVIEW - CLICK BELOW
Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its major product ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases. The company has just administered the first dose of its dose escalation study into the drug.